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Liquid-based endometrial cytology: cyto-histological correlation in a population of 917 women
Objective: Liquid-based cytology, because of its capacity to reduce the obscuring factors and to provide
thin-layer specimens, represents an opportunity to reevaluate endometrial cytology. In order to assess the utility
of the liquid-based method in endometrial diagnosis, we evaluated its accuracy in comparison with histology.
Methods: Nine hundred and seventeen women scheduled for hysteroscopy were enrolled in the study. After
providing informed consent, all the women proceeded sequentially to hysteroscopy, endometrial cytology and
then biopsy endometrial sampling.
Results: Cyto-histological correlations were possible in 519 cases (57%): in 361 (39%) cases the biopsy was
inadequate, in 15 (2%) the cytology was inadequate, and in 22 (2%) both were inadequate. At biopsy 25 (3%)
women had adenocarcinoma, 5 (1%) had adenomatous atypical hyperplasia and 21 (2%) had simple non
atypical hyperplasia. At cytology two adenocarcinomas and one adenomatous atypical hyperplasia were
underrated as atypical hyperplasias and as non-atypical hyperplasia; two simple non-atypical hyperplasias were
reported as negative; and eight cases were false positive (non-atypical hyperplasia at cytology, negative at biopsy).
In our population, the cytology provided sufficient material more often than biopsy (P < 0.04). Sensitivity was
estimated at 96%, specificity at 98%, positive predictive value at 86% and negative predictive value at 99%.
Conclusions: We concluded that endometrial cytology may be an efficient diagnostic method. It could be
applied to selected patients solely or in association with ultrasonography. The combination of these two
noninvasive procedures may improve their diagnostic accuracy and reduce unnecessary hysteroscopies, thereby
producing benefits for women and society.
Keywords: endometrial neoplasms, uterine neoplasms, cytodiagnosis, cytological techniques, ThinPrep, LBC,
liquid-based cytology
Introduction
Endometrial adenocarcinoma ranks fifth in incidence
among malignancies in women, and it is the most
frequent malignancy of the female genital tract in
developed countries. The majority of the cases are
sporadic whereas about 10% are hereditary. Most
important among the latter, is the autosomal domi-
nantly inherited non-polyposis colorectal cancer
caused by mutation of a DNA mismatch repair gene
that determines constitutive microsatellite instability
and Cowden syndrome in patients with germ line
PTEN inactivation.1–10
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Two subtypes of endometrial carcinoma, named
type I and type II, have been described on the basis of
their different age of development, aetiopathogenesis,
histopathological features and prognosis. Type I
adenocarcinoma, which accounts for most cases
(approximately 80%), occurs in peri-menopausal
women, is oestrogen dependent, more often well
differentiated and endometrioid, and has a favourable
behaviour with appropriate therapy. Conversely, the
rare type II endometrial adenocarcinoma affects older
postmenopausal women, is oestrogen independent,
predominantly of serous papillary or clear cell histo-
type, and has a worse prognosis with a high incidence
of upper abdominal metastases and dissemination.
Type I adenocarcinoma is frequently preceded by
endometrial hyperplasia whereas type II is not. Indeed,
the precursor of serous papillary endometrial carci-
noma is serous endometrial intraepithelial carcinoma
(also named surface serous carcinoma or minimal
uterine serous carcinoma) which frequently arises on
atrophic endometrium. Moreover, type I carcinomas
are associated with mutations in the K-ras proto-
oncogene, and in the PTEN tumour suppressor gene,
and often show microsatellite instability, but do not
usually have mutations in the p53 tumour suppressor
gene. By contrast, type II carcinomas show frequent
p53 mutations, but rarely have microsatellite insta-
bility, K-ras or PTEN mutations.1, 8, 9, 11–14
Most women with endometrial cancer are diagnosed
at an early stage as vaginal bleeding is an early, even if
nonspecific, presenting symptom.1, 15, 16 Unlike cervi-
cal carcinoma, no mass screening programmes for the
early detection of endometrial carcinoma have been
organized. The early presenting symptoms and the
good prognosis of the majority of endometrial adeno-
carcinomas may explain the limited interest in screen-
ing this neoplasm in spite of its high frequency and the
existence of morphological precursors. On the other
hand, there has not been a test comparable to cervico-
vaginal cytology for tolerability, sensitivity, specificity
and low cost.
Endometrial cytology has been hampered in its
dissemination by difficulty in its interpretation due to
the common presence of excess blood and overlapping
cells. In addition, the physiology of the endometrium
may determine difficulties in the cytopathological
interpretation of the specimens, especially by non-
pathologists.17–20
Liquid-based cytology represents an opportunity to
re-evaluate endometrial cytology; an increasing inter-
est in it is demonstrated by a number of articles
which report interesting results in terms of diagnostic
accuracy.21–23
In order to assess the utility of liquid-based cytology
in endometrial diagnosis we evaluated the accuracy of
liquid-based endometrial cytology compared with the
histological diagnosis in a group of 917 women
scheduled for hysteroscopy.
Patients and methods
Thepatients included inthis studywere917consecutive
women scheduled for hysteroscopy in which the
absence of cervical stenosis made the investigation
possible. After providing informed consent, all the
women proceeded sequentially to hysteroscopy,
endometrial cytologyandbiopsyendometrial sampling.
Their median age was 52 years (range 23–89). In
the majority of the cases, 663 women (72%), hyster-
oscopy was required for thickened endometrium
(>4 mm) as evaluated by transvaginal ultrasonogra-
phy; 345 (38%) women were referred for abnormal
uterine bleeding; 74 (8%) were tamoxifen users.
Cytological sampling was performed using the Endo-
flower device (RI-MOS; Mirandola, Modena, Italy)
(Figure 1) made of a radio-opaque technopolymer
material measuring 3 mm in diameter. It consists of a
mandrel with a shaped tip containing micro holes
on curved thin arms that slide inside an outer sheath.
An adjustable positioner is placed on the outer sheath to
determine the correct insertion depth. Before the intro-
duction of the device into the uterus, the umbrella-
shaped tip was withdrawn inside the introducer. Once
inside the uterine cavity, the umbrella-shaped tip was
released and rotated clockwise and counter-clockwise.
Figure 1. Endoflower device.
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After the collection of endometrial material, the tip was
withdrawn inside the introducer to prevent cervical
contamination and the device removed. Outside the
uterus, the device was cleaned with gauze to remove
cervical cell contamination and then the umbrella-
shaped tip was exposed and immersed in the Cytolyt
(Cytyc Corporation, Boxborough, MA, USA) vial and
vigorously rotated. The device was removed from the
vial and the vial was labelled with the appropriate
patient information and transported to the Department
of Pathology where the samples were processed and the
diagnoses made.
After centrifugation (300 g for 5 minutes), the
pellet containing the cells was transferred into a vial
containing PreservCyt (Cytyc Corporation). Preserv-
Cyt mildly fixes the cells within 10–15 minutes so
preserving them for at least 3 weeks at room tem-
perature. Blood and mucus were eliminated by means
of washing through the succession of centrifugation
and resuspension in N-acetyl-l-cisteine (mucolysis;
before fixation in PreservCyt) and ⁄or acetic acid
(haemolysis; after fixation in PreservCyt). The vial
was inserted into the ThinPrep 2000 automated slide
processor (Cytyc Corporation), which, in about
1 minute and 30 seconds, prepares a smear in a thin
layer within a microscopic field measuring 20 mm in
greatest dimension. The slides were stained with
routine Papanicolaou stain.
Histological sampling was performed using the
Endoram device (RI-MOS). Endometrial samples were
routinely fixed in neutral buffered formol, embedded
in paraffin and stained with haematoxylin and eosin.
Cytological and histological diagnoses were execu-
ted blindly by two cyto-histo-gynaecopathologists
(A.M.B. and G.L.T.). In cases of discordant diagnosis
both pathologists reviewed the case together and
reached an agreement on the diagnosis. The slides
were considered inadequate when there were less
than five evaluable endometrial clusters (endometrial
cytology) or severe fragmentation or scarcity of the
endometrial tissue (endometrial biopsy). If the first
cytological or histological slide was inadequate a
second slide was prepared. When the second one
was also unsatisfactory the diagnosis was considered
as inadequate.
The cytological diagnosis was given according to
the criteria previously reported.24 We considered
four categories: normal (grouping proliferative, secre-
tory and atrophic endometrium; Figures 2–4), non-
atypical hyperplasia (Figure 5), atypical hyperplasia
and carcinoma (Figure 6a–d), on the basis of the
architectural and cytological features of the endome-
trial clusters, considering all anamnestic and clinical
information. Table 1 outlines the main diagnostic
criteria used. Cytological specimens with occasional
endometrial clusters showing non-atypical hyperplas-
tic features were considered negative when hyster-
oscopy and ⁄or ultrasonography diagnosed an
endometrial polyp.
The histological diagnosis conformed to the World
Health Organization criteria.1
Due to the small number of pathological specimens,
statistical analyses were performed by categorizing
the cases as non-pathological and pathological
Figure 2. Proliferative endometrium: three-dimensional
cylindrical endometrial cluster formed by isomorphic cells
with scant cytoplasm and regular nuclei.
Figure 3. Secretory endometrium: endometrial placards
formed by isomorphic cells with large clear cytoplasm and
regular nuclei.
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(hyperplasia, atypical hyperplasia and carcinoma). The
sensitivity was calculated by dividing the true patholo-
gical cases diagnosed by endometrial cytology by the
total number of patients with endometrial pathology
and multiplying by 100. The specificity was calculated
by dividing the number of true negative cases diagnosed
by endometrial cytology by the total number of women
who did not have endometrial disease and multiplying
by 100. The positive predictive value was calculated by
dividing the true pathological cases by the total number
of true positive cytological specimens and the false-
positive cases and multiplying by 100. The negative
predictive value was calculated by dividing the true
negative cases by the total of true negative and the false-
negative cytological specimens and multiplying by 100.
The chi-squared test was used to compare the number
of unsatisfactory cytological specimens with that of
endometrial biopsies. Statistical significance was
judged as P < 0.04. Data analysis was performed using
the Glaz SA 3.03 Version statistical package (Mc Graw-
Hill, New York, NY, USA).
Results
In 815 cases (89%) hysteroscopy did not detect
features of hyperplasia or neoplasia.
Thirty-seven (4%) cytologies and 383 biopsies
(42%) were inadequate. Of the 383 inadequate
endometrial biopsies, 350 (38%) were considered
inadequate by the gynaecologists because of the
scarcity of the sampled tissue and no specimens were
transported to the pathologists; the remaining 33
(4%) inadequate cases were judged inadequate by
pathologists during histopathological evaluation.
In 361 (39%) cases only the biopsy was inadequate;
in 15 (2%) only the cytology was inadequate; and in
22 (2%) cases both the biopsy and the cytology were
inadequate.
Cyto-histological correlation was possible in the
remaining 519 cases (57%). The majority of inad-
equate cases (91%) were women aged older than 50.
Evaluation of the biopsies determined that 25 (3%)
women had adenocarcinoma, five (1%) had adeno-
matous atypical hyperplasia and 21 (2%) had simple
Figure 4. Atrophic endometrium: small three-dimensional
endometrial cluster formed by isomorphic cells, with scant
cytoplasm and hyperchromatic regular nuclei.
Figure 5. Non-atypical hyperplasia: wide three-dimen-
sional cluster with considerable cellular crowding and
architectural disorder.
(a) (b)
(c) (d)
Figure 6. Endometrial adenocarcinoma: small endometrial
clusters (a–c) with papillary configuration (b) in a
inflammatory-necrotic background (d).
A. M. Buccoliero et al.244
Cytopathology 2007, 18, 241–249 ª 2007 The Authors
Journal compilation ª 2007 Blackwell Publishing Ltd
T
a
b
le
1
.
M
a
in
d
ia
g
n
o
st
ic
cr
it
e
ri
a
E
n
d
o
m
e
tr
ia
l
C
e
ll
s
B
a
ck
g
ro
u
n
d
E
p
it
h
e
li
a
l
ce
ll
s
S
tr
o
m
a
l
ce
ll
s
Q
u
a
n
ti
ty
A
rc
h
it
e
ct
u
re
P
o
la
ri
ty
C
y
to
p
la
sm
N
u
cl
e
u
s
P
ro
li
fe
ra
ti
v
e
A
b
u
n
d
a
n
t
T
h
re
e
-d
im
e
n
si
o
n
a
l
cy
li
n
d
ri
ca
l
cl
u
st
e
rs
P
re
se
rv
e
d
S
ca
n
t
Is
o
m
o
rp
h
ic
,
fi
n
e
ly
g
ra
n
u
la
r
ch
ro
m
a
ti
n
,
sm
a
ll
o
r
a
b
se
n
t
n
u
cl
e
o
li
S
p
in
d
le
-s
h
a
p
e
d
C
le
a
n
S
e
cr
e
to
ry
A
b
u
n
d
a
n
t
W
id
e
th
re
e
-d
im
e
n
si
o
n
a
l
cy
li
n
d
ri
ca
l
cl
u
st
e
rs
o
r
b
i-
d
im
e
n
si
o
n
a
l
p
la
ca
rd
s
P
re
se
rv
e
d
L
a
rg
e
Is
o
m
o
rp
h
ic
,
d
is
p
e
rs
e
d
ch
ro
m
a
ti
n
,
sm
a
ll
o
r
a
b
se
n
t
n
u
cl
e
o
li
E
p
it
h
e
li
o
id
M
o
d
e
ra
te
ly
in
fl
a
m
m
a
to
ry
(l
a
te
se
cr
e
to
ry
)
A
tr
o
p
h
ic
S
ca
n
t
S
m
a
ll
th
re
e
-d
im
e
n
si
o
n
a
l
cl
u
st
e
rs
P
re
se
rv
e
d
S
ca
n
t
S
m
a
ll
,
is
o
m
o
rp
h
ic
,
d
e
n
se
ch
ro
m
a
ti
n
,
sm
a
ll
o
r
a
b
se
n
t
n
u
cl
e
o
li
A
b
u
n
d
a
n
t,
sp
in
d
le
-s
h
a
p
e
d
C
le
a
n
,
m
u
lt
in
u
cl
e
a
te
d
h
is
ti
o
cy
te
s
N
o
n
-a
ty
p
ic
a
l
h
y
p
e
rp
la
si
a
A
b
u
n
d
a
n
t
W
id
e
th
re
e
-d
im
e
n
si
o
n
a
l
cl
u
st
e
rs
w
it
h
co
n
si
d
e
ra
b
le
ce
ll
u
la
r
cr
o
w
d
in
g
A
rc
h
it
e
ct
u
ra
l
d
is
o
rd
e
r
S
ca
n
t
Is
o
m
o
rp
h
ic
,
fi
n
e
ly
g
ra
n
u
la
r
ch
ro
m
a
ti
n
,
sm
a
ll
o
r
a
b
se
n
t
n
u
cl
e
o
li
S
p
in
d
le
-s
h
a
p
e
d
M
o
d
e
ra
te
ly
in
fl
a
m
m
a
to
ry
A
ty
p
ic
a
l
h
y
p
e
rp
la
si
a
A
b
u
n
d
a
n
t
W
id
e
th
re
e
-d
im
e
n
si
o
n
a
l
cl
u
st
e
rs
w
it
h
v
a
ri
a
b
le
ce
ll
u
la
r
cr
o
w
d
in
g
A
rc
h
it
e
ct
u
ra
l
d
is
o
rd
e
r
V
is
ib
le
V
a
ri
a
b
ly
p
le
o
m
o
rp
h
ic
,
g
ra
n
u
la
r
ch
ro
m
a
ti
n
,
p
re
se
n
ce
o
f
n
u
cl
e
o
li
S
ca
n
t,
sp
in
d
le
-s
h
a
p
e
d
M
o
d
e
ra
te
ly
in
fl
a
m
m
a
to
ry
C
a
rc
in
o
m
a
A
b
u
n
d
a
n
t
E
n
d
o
m
e
tr
ia
l
cl
u
st
e
rs
w
it
h
v
a
ri
a
b
le
d
im
e
n
si
o
n
s
a
n
d
ce
ll
u
la
r
cr
o
w
d
in
g
;
lo
ss
o
f
ce
ll
u
la
r
co
h
e
si
o
n
A
rc
h
it
e
ct
u
ra
l
d
is
o
rd
e
r
V
is
ib
le
P
le
o
m
o
rp
h
ic
,
co
a
rs
e
ly
g
ra
n
u
la
r
ch
ro
m
a
ti
n
,
p
re
se
n
ce
o
f
n
u
cl
e
o
li
a
n
d
/o
r
m
a
cr
o
n
u
cl
e
o
li
S
ca
n
t,
sp
in
d
le
-s
h
a
p
e
d
In
fl
a
m
m
a
to
ry
Liquid-based endometrial cytology 245
Cytopathology 2007, 18, 241–249 ª 2007 The Authors
Journal compilation ª 2007 Blackwell Publishing Ltd
non atypical hyperplasia. Endometrial cytology diag-
nosed 24 endometrial carcinoma cases, six hyperplas-
tic with atypia cases and 48 hyperplastic without
atypia cases. One endometrial adenocarcinoma,
occurring in a woman on tamoxifen, was initially
only detected by endometrial cytology while the
biopsy was inadequate (as judged by the gynaecolo-
gist). The cytological diagnosis was confirmed by a
subsequent endometrial curettage (Table 2).
In the series of 519 cases in which both endometrial
biopsy and cytology were adequate, endometrial
cytology recognized 23 endometrial carcinoma cases,
six hyperplastic with atypia cases and 28 hyperplastic
without atypia cases (Table 3). Two endometrial
adenocarcinomas and one atypical hyperplasia were
underrated by endometrial cytology and resulted as
atypical hyperplasias and as non-atypical hyperplasia
respectively. Two simple non-atypical hyperplasias
were reported as negative by cytology. Eight cases
were false positive by cytology (non-atypical hyper-
plasias by cytology, negative on biopsy).
When we categorized the cases studied as non-
pathological and pathological, cyto-hystological con-
cordance was 98%; sensitivity was estimated at 96%,
specificity at 98%, positive predictive value at 86% and
negative predictive value at 99%. Endometrial cytology
provided sufficient material for the diagnosis signifi-
cantly more often than endometrial biopsy (P < 0.04).
Discussion
The incidence of endometrial carcinoma has increased
and currently represents the most prevalent malig-
nant gynaecological tumour. This increase has
primarily been attributed to the increase in the
average life expectancy of women, the increase in
the incidence of risk factors such as obesity, low
parity, hypertension and diabetes, and also to the
reduction in the incidence of invasive cervical carci-
noma. Furthermore, the frequent administration of
exogenous oestrogens, particularly without the differ-
entiating effects of progestens, and of tamoxifen (a
drug having an oestrogenic effect on the female
genital tract often used in women with breast cancer)
have been identified as additional factors responsible
for the increased incidence of endometrial adenocar-
cinoma.1, 2, 7–10, 25–27 The prevention, detection of the
pre-neoplastic conditions, early diagnosis of neoplastic
lesions and appropriate treatment are efficient
anti-cancer strategies.
Thin-layer cytology may represent a useful method
for detecting endometrial pre-neoplastic conditions
Table 2. Histological and cytological
results (917 women)
Histology, n (%) Cytology, n (%)
Non-pathological 483 (53) 802 (88)
Pathological 51 (5) (25 adenocarcinomas,
5 adenomatous atypical
hyperplasias, 21 simple
non-atypical hyperplasias)
78 (8) (24* adenocarcinomas,
6 atypical hyperplasias, 48
non-atypical hyperplasias)
Inadequate 383 (42) 37 (4)
Total 917 (100) 917 (100)
*Twenty-three adenocarcinomas were diagnosed both by cytology and on biopsy;
one was detected by cytology only (endometrial biopsy did not obtain sufficient
diagnostic tissue as judged by gynaecologist) and subsequently confirmed by an
endometrial curettage.
Table 3. Histological and cytological
results (519 women in which both
biopsy and cytology were adequate)
Histology, n (%) Cytology, n (%)
Non-pathological 468 (90) 462 (89)
Pathological 51 (10) (25 adenocarcinomas,
5 adenomatous atypical
hyperplasias, 21 simple
non-atypical hyperplasias)
57 (11) (23 adenocarcinomas,
6 atypical hyperplasias,
28 non-atypical hyperplasias)
Total 519 (100) 519 (100)
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(hyperplasias or serous endometrial intraepithelial
carcinoma) and neoplastic lesions at an early stage.
Even if abnormal uterine bleeding, particularly in the
postmenopausal age, is generally regarded both by
clinicians and women as an alarming and serious
symptom, only in a minority of the cases is
a precancerous or cancerous condition detected.
Instead, the more commonly encountered cause of
uterine bleeding is atrophic endometrium. Iatrakis
et al.16 concluded that, in a group of 628 patients with
a median age of 52 years, atrophic endometrium was
found in 83% of the cases and carcinoma of the
endometrium in only 11%. A similar percentage was
reported by Choo et al.15 which retrieved atrophic
endometrium and endometrial adenocarcinoma in
82% and 7% respectively. Only a small number of
endometrial carcinomas, ranged between 0.07% and
0.6%,28–31 are incidentally diagnosed in asympto-
matic patients. This last percentage is higher in
women with risk factors. Particularly, Gro¨nroos et al.32
estimated the incidence of invasive or pre-invasive
endometrial lesions as 6.3% in a group of 597
asymptomatic diabetic women.
In this context, the relatively low incidence of
neoplastic conditions in patients with postmenopau-
sal bleeding may discourage the use of an invasive
diagnostic procedure initially and the low prevalence
rate of the disease among asymptomatic women
without risk factors dissuades from screening these
women. However, the presence of risk factors may
require careful surveillance of symptomatic and
asymptomatic women.
Several diagnostic procedures are available in the
investigation of the endometrium. Hysteroscopy,
endometrial biopsy, and dilatation and curettage
are efficient diagnostic methods. The optimal
circumstance is an endometrial biopsy under hystero-
scopic control. Nevertheless, these procedures are
not tolerated well despite the introduction of mini-
hysteroscopes and flexible hysteroscopes which have
reduced the discomfort produced by traditional
hysteroscopy.33, 34 In addition, endometrial biopsy,
particularly in postmenopausal women, may not
obtain endometrial tissue sufficient for histopatho-
logical evaluation. In our previous study of 107
asymptomatic postmenopausal women with thin
endometrium (<4 mm), biopsy gave sufficient ma-
terial for the diagnosis in only 24% of the cases.22
Analogously, Elsandabesee and Greenwood35 esti-
mated that there is a 27% probability of getting an
adequate endometrial sample in women with thin
endometrium and Bakour et al.36 affirmed that in
cases with atrophic endometrium and ⁄or focal
lesion only minimal tissue can be obtained.
Transvaginal ultrasonography is a noninvasive
method but its specificity is often low, particularly
in tamoxifen users where the endometrial thickness
is frequently overestimated because of oedema.37 A
recent meta-analysis of the diagnostic accuracy of
endometrial thickness measurements by transvaginal
or transabdominal ultrasound involving 9,031
women with postmenopausal bleeding and covering
57 separate studies reported that using a £5 mm
cut-off level, a positive test raised the probability of
carcinoma from 14.0% to 31.3% while a negative
test reduced it to 2.5%. These results persuaded the
authors to conclude that ultrasonography has lim-
ited predictive value for endometrial hyperplasia or
carcinoma.38
Regarding traditional endometrial cytology,
despite several encouraging results having reported
sensitivity and specificity reaching 96%,39–43 its
acceptance has been hampered as a consequence
of technical and diagnostic difficulties. In 1955,
Hecht44 warned of the danger of the use of the
endometrial cytology and several years later, in
1990, Caubel et al.45 further supported this warning,
advising that the endometrial cytological diagnosis
should always be confirmed by a histological diag-
nosis.
Endometrial cytology should be reconsidered as a
diagnostic tool when coupled with liquid-based
processing. The characteristics of this method,
reduction in the obscuring factors, distribution of
the cells on a thin layer, possibility of obtaining
more than one slide available for further investi-
gation, i.e. immunohistochemistry, may really
represent an interesting opportunity on condition
that an appropriate device is utilized, the diagnostic
interpretation of the specimens is delegated to
pathologists or to people skilled in endometrial
physio-patho-morphology, and that, in cyclic
women, the timing of the sampling is correct
(secretory phase). In particular, the correct sampling
timing is important due to the possible problematic
differential diagnoses between proliferative endo-
metrium and non-atypical hyperplastic endometrium.
Some recent studies emphasized the diagnostic
potentiality of endometrial thin-layer cytology. In
2003, Garcia et al.21 performed a prospective study
of 103 symptomatic women and reported a very
good specificity (96%), good (78%) sensitivity and a
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low (15%) inadequate rate (lower than endometrial
biopsy, calculated at 26%). In the same year, our
group22 documented a cyto-histological concordance
of 98% and a low inadequate rate (18%) in a
population of 162 women. In 2005, Papaefthimiou
et al.23 reported that liquid-based endometrial cyto-
logy allows for the application of common diagnostic
criteria, therefore making possible a nearly perfect
interobserver and intraobserver agreement. The low
percentage of inadequate specimens, the high
sensitivity, specificity, and positive and negative
predictive values seen in our present study support
these findings.
The high inadequate rate of endometrial biopsies in
our collection may be related to the predominance of
peri-postmenopausal women (91% of the inadequate
cases were women older than 50 years) and of
negative cases (Tables 2 and 3). On the other hand,
the presence of a case of adenocarcinoma undiag-
nosed by biopsy but detected by cytology only
emphasizes that inadequate biopsy, particularly in
symptomatic women, does not exclude an endome-
trial pathology.46
In conclusion, we consider endometrial cytology an
efficient diagnostic method. It could be applied to
selected patients solely or in association with trans-
vaginal ultrasonography. The combination of these
procedures may improve their diagnostic accuracy47
and reduce unnecessary hysteroscopies for women as
well as provide social benefits as a consequence of the
reduction of a more invasive and more expensive
diagnostic procedure.
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